GleamWall
中文EN

CV CapsoVision, Inc

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1378325 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.4%
TTM net income YoY-29.6%
TTM EPS YoY87.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin49.7%
Operating margin-212.1%
Net margin-210.1%
FCF margin-210.3%
EBITDA margin-210.4%

Returns

ROE-125.0%
ROA-100.1%
ROIC (approx.)-99.6%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets19.5%
Debt / equity0.00x
Current ratio5.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.2%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$3.57M$3.64M$2.79M$3.92M$3.54M$3.31M$2.78M$3.45M
Cost of revenue$1.80M$1.77M$1.46M$1.96M$1.62M$1.50M$1.29M$1.72M
Gross profit$1.76M$1.87M$1.33M$1.95M$1.91M$1.81M$1.49M$1.73M
R&D expense$4.80M$5.31M$4.43M$5.72M$6.09M$3.39M$3.11M$3.12M
SG&A expense$2.29M$2.21M$1.90M$1.75M$2.07M$1.22M$1.81M$1.45M
Operating income-$7.38M-$7.58M-$7.09M-$7.46M-$8.02M-$4.65M-$5.38M-$4.63M
Pretax income-$7.34M-$7.48M-$7.03M-$7.37M-$7.92M-$4.62M-$5.38M-$4.63M
Income tax$0$0$0$24,000$0$0$0$11,000
Net income-$7.34M-$7.48M-$7.03M-$7.39M-$7.92M-$4.62M-$5.38M-$4.64M
EBITDA-$7.33M-$7.52M-$7.04M-$7.41M-$7.96M-$4.60M-$5.33M-$4.58M
EPS (basic)-0.15-0.15-0.15—-0.17-2.02-2.49—
EPS (diluted)-0.15-0.15-0.15—-0.17-2.02-2.49—
Weighted avg. shares (diluted)50.57M49.94M47.46M—46.22M2.29M2.16M—
Balance sheet
Receivables$2.46M$2.27M$1.93M$2.50M$1.87M$1.85M—$2.00M
Inventory$4.75M$4.70M$3.49M$2.99M$3.19M$3.04M—$2.63M
Current assets$31.05M$17.28M$24.50M$16.67M$24.05M$7.80M—$14.85M
PP&E, net$508,000$562,000$620,000$611,000$640,000$683,000—$720,000
Total assets$32.75M$18.57M$25.95M$18.16M$25.66M$9.55M—$16.80M
Current liabilities$6.12M$5.16M$5.36M$4.43M$4.63M$4.22M—$1.80M
Total liabilities$6.38M$5.40M$5.72M$4.90M$5.22M$4.91M—$2.69M
Shareholders' equity$26.37M$13.17M$20.22M$13.26M$20.44M-$138.99M-$134.70M-$129.51M
Shares outstanding53.57M50.03M49.84M46.87M46.80M2.46M—2.09M
Cash flow statement
Operating cash flow-$7.04M-$8.40M-$6.07M-$7.69M-$5.67M-$4.53M-$4.99M-$5.40M
Capital expenditure$22,000$0$48,000$8,000$12,000$30,000$40,000$0
Free cash flow-$7.06M-$8.40M-$6.11M-$7.69M-$5.68M-$4.56M-$5.03M-$5.40M
Investing cash flow-$22,000$0-$48,000-$8,000-$12,000-$30,000-$40,000$0
Financing cash flow$19.75M-$443,000$13.95M$15,000$22.39M$1.17M$34,000$5.00M
Depreciation & amortization$58,000$58,000$56,000$55,000$54,000$55,000$52,000$51,000
Stock-based compensation$952,000$563,000$334,000$197,000$307,000$170,000$152,000$113,000

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.